Back to Search Start Over

Clinical impact of rebiopsy among patients with epidermal growth factor receptor‐mutant lung adenocarcinoma in a real‐world clinical setting

Authors :
Yunha Nam
Ho Cheol Kim
Young‐Chul Kim
Seung Hun Jang
Kye Young Lee
Shin Yup Lee
Sang Hoon Lee
Sung Yong Lee
Seong Hoon Yoon
Jeong‐Seon Ryu
Tae Won Jang
Yoon Soo Chang
Seung Joon Kim
Chan Kwon Park
Jeong Eun Lee
Chi Young Jung
Chang‐Min Choi
Source :
Thoracic Cancer, Vol 12, Iss 6, Pp 890-898 (2021)
Publication Year :
2021
Publisher :
Wiley, 2021.

Abstract

Abstract Background In this study, we investigated the risk factors of acquired T790M mutation among patients with lung adenocarcinoma with epidermal growth factor receptor (EGFR) tyrosine mutation who were treated with EGFR‐tyrosine kinase inhibitors (TKIs). The aim was to identify the clinical impact of rebiopsy. Methods This multicenter, retrospective cohort study was conducted in South Korea from January 2007 to June 2017. Patients with adenocarcinoma with EGFR mutation who underwent rebiopsy and were treated with EGFR‐TKIs were included. Results Of a total of 352 patients, T790M mutation was identified in 156 (41.9%) at the time of rebiopsy. The median duration from initial biopsy to rebiopsy was 17 months. Univariate logistic regression analysis revealed associations of exon 19 deletion (odds ratio [OR], 1.643; p = 0.026), absence of L858R (OR, 0.627; p = 0.042), and previous EGFR‐TKI treatment duration (OR, 1.039; p

Details

Language :
English
ISSN :
17597714 and 17597706
Volume :
12
Issue :
6
Database :
Directory of Open Access Journals
Journal :
Thoracic Cancer
Publication Type :
Academic Journal
Accession number :
edsdoj.979c8589aab943f3a9103dd3b5e3cb81
Document Type :
article
Full Text :
https://doi.org/10.1111/1759-7714.13857